49 results about "Methylone" patented technology

The invention relates to the technical field of optical radiation free-radical polymerized new materials, especially to a novel synthesis technological process of commercial photoinitiator compounds of (diphenylphosphine oxide)(mesitylene)ketone and (phenylphosphine oxide)bis(mesitylene ketone). According to the invention, 1,3,5-trimethyl-2-(trichloromethyl)-benzene is used as a key raw material and is respectively subjected to a condensation reaction with corresponding organic phosphine precursors so as to prepare the target compounds. In comparison with a known technological route, the technology disclosed in the application has significant advantages such as novelty of the chemical reaction process, economical cost, competitiveness and environmental friendliness.

The invention relates to a preparation method of 2-p-chlorobenzyl pyridine, comprising the following steps of: firstly adding chlorobenzene and alchlor to 2-pyridine formyl chloride hydrochloride for reaction so as to obtain 1-(4-chlorphenyl)-1-(2-pyridyl) ketone; and then adding diglycol, hydrazine hydrate and potassium hydroxide to the prepared 1-(4-chlorphenyl)-1-(2-pyridyl) ketone for reaction so as to obtain the 2-p-chlorobenzyl pyridine. The 2-p-chlorobenzyl pyridine produced by the method is used as an intermediate for preparing chlorpheniramine and has high product purity and simple and convenient process, and the chlorpheniramine prepared by using the 2-p-chlorobenzyl pyridine accords with Chinese pharmacopoeia; in addition, the invention has low cost, easy industrialization and outstanding economic benefit and social benefit.

A novel hydroxyalkyl phenyl ketone: (1-hydroxycylohexyl)[4-(2- hydroxy ethoxy)phenyl] methanone, its preparing process and its application as the trigger for optical solidification are disclosed. Said trigger can effectively and optical trigger the polymerization between unsaturated compound and resin. Its special molecular structure can prevent migration, odoring and yellowing.

The invention relates to an asymmetric synthesis method for an anti-allergy drug carbinoxamine. The method specifically comprises the following steps: oxidizing (4-chlorophenyl)(2-pyridyl)ketone to obtain (4-chlorophenyl)(2-pyridyl)ketone-N-oxide; by taking monosulfonylated chiral diamine and metal ruthenium/rhodium/iridium complex as catalysts and sodium formate or a formic acid and triethylamine mixture or isopropanol as a hydrogen source, reducing the (4-chlorophenyl)(2-pyridyl)ketone-N-oxide through asymmetry transfer hydrogenation to prepare (S)-(4-chlorophenyl)(2-pyridyl)methanol-N-oxide; reducing the (S)-(4-chlorophenyl)(2-pyridyl)methanol-N-oxide to obtain (S)-(4-chlorophenyl)(2-pyridyl)methanol; and performing etherification reaction on the (S)-(4-chlorophenyl)(2-pyridyl)methanol and 2-chloro-N,N-dimethylethylamine to obtain the product, wherein the overall yield is 74.6%.

Substituted (E)-N-(1-phenylethylidene)benzohydrazide analogs or (3-(5-chloro-2-hydroxyphenyl)-4-METHYL-1 H-pyrazol-1-YL)(3- (morpholinosulfonyl)phenyl)methanone, derivatives thereof, and related compounds are useful as inhibitors of lysine-specific histone demethylase, including LSD1. Synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1 (lysine-specific demethylase). A pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, and one or more of: (a) at least one agent known to increase histone demethylase activity; (b) at least one agent known to decrease histone demethylase activity; (c) at least one agent known to treat a disorder of uncontrolled cellular proliferation; (d) at least one agent known to treat a neurodegenerative disorder; (e) instructions for treating a neurodegenerative disorder; or (f) instructions for treating a disorder associated with uncontrolled cellular proliferation.

The invention discloses a method for preparing an SGLT2 (Sodium-Dependent Glucose Transporters 2) inhibitor intermittent. The method comprises the following steps: (1) carrying out a Friedel-Crafts reaction on 5-halogen-2-chlorobenzoic acid and fluorobenzene so as to obtain (5-halogen-2-chlorphenyl) (4-fluorophenyl) ketone; (2) under the action of an organic alkali, carrying out a substitution reaction on (5-halogen-2-chlorphenyl) (4-fluorophenyl) ketone and ethanol, and after the reaction is completed, treating so as to obtain (5-halogen-2-chlorphenyl) (4-ethyoxyl phenyl) ketone; (3) carryingout a carbonyl reduction reaction on the (5-halogen-2-chlorphenyl) (4-ethyoxyl phenyl) ketone under the action of a reducing agent, thereby obtaining the SGLT2 inhibitor intermittent. By adopting themethod, an ethoxy metal reagent and DMSO (Dimethyl Sulfoxide) (or DMF (Dimethyl Formamide)) are replaced by the inorganic alkali and ethanol, so that not only is the cost effectively reduced, but also the environment can be protected.

The present invention concerns a topical, cosmetic or pharmaceutical preparation containing a combination of 3 or 4 solar filters comprising: -one or two UVA filters to obtain a critical wavelength >370 nm, chosen from among: ( i) - 5, 6, 5, 6-tetraphenyl-3, 3'-(1,4-phenylene)-bis[1, 2, 4]triazine; (ii) 1,1'-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone; (iii)- Butyl Methoxydibenzoylmethane (BMDBM), in a quantity less than 2% by weight with regard to the total weight of said composition; (iv) - Hexyl -[4-(diethylamino)-2- hydroxybenzoyl]benzoate, -2,4-Bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6- (4-methoxyphenyl)-1, 3, 5-triazine = (BEMT), - one or two selected from the group consisting of diethylhexyl butamido triazone, ethylhexyl triazone, and filtersof tris-biphenyl triazine, ethylhexyl salicylate, phenylbenzimidazole sulfonic acid and TiO2 in an amount of from 3% by weight to 7% by weight relative to the total weight of the composition.

The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2- yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.

The invention relates to a new method for preparing 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfanyl)phenyl]acetone. The method comprises the step of reacting Grignard reagent of formula (II) with isoxazole-2-yl-(6-methylpyridine-3-yl)-ketone of formula (III) at minus 20 to 0 DEG C to obtain the 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfanyl)phenyl]acetone of formula (I). Compared with the prior art, the method has the advantage of lowering the explosive risk of the reaction system.

The invention discloses phenyl-(pyrazolo[1,5-alpha]pyridin-3-yl)methanone derivatives, which are compounds shown as a general formula (I) or pharmaceutically acceptable salts thereof. The compounds orthe pharmaceutically acceptable salts thereof can be applied to uric acid excretion promotion for treating or preventing hyperuricemia and gout, or can be used for treating diabetes.

Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders.

The invention relates to a 2-substituted-3-arylketone-6-(5-methyl-2-phenyl-4-ehtyoxyloxazole)benzofuran compound with the structural formula as shown in the specification. Compared with the prior art, the novel compound is prepared by introducing (5-methyl-2-phenyloxaole-4-yl)ethyoxyl to the 6 site of benzofuran by taking 3-ketone substituent benzofuran as the center of an aromatic ring; a preparation method of the compound is established and optimized; the prepared novel compound is subjected to an antibacterial screening experiment; the primary in-vitro antibacterial experiment confirms that the prepared novel compound has excellent broad-spectrum antibacterial activity and can be used for preparing novel antibacterial drugs.

The invention discloses a preparation method of (3-amino-azetidine-1-yl)-cyclopropyl-ketone. The preparation method comprises the following steps: dissolving azetidine-3-ketone hydrochloride in a solvent under an alkaline condition, adding an acylation reagent for reaction to obtain 1-cyclopropanecarbonyl-azetidine-3-ketone; dissolving the 1-cyclopropanecarbonyl-azetidine-3-ketone in a solvent, adding benzylamine, stirring and dissolving the benzylamine, and adding a reducing agent for reaction at-5-5 DEG C to obtain (3-benzylamino-azetidine-1-yl)-cyclopropyl-ketone; dissolving 3-boroamino-azetidine-1-yl)-cyclopropyl-ketone in a solvent to react with a reducing agent in the presence of a catalyst to obtain (3-amino-azetidine-1-yl)-cyclopropyl-ketone. The raw materials used in the preparation method provided by the invention are low in price and wide in source, six steps of reaction of an original synthesis method are reduced to three steps of reaction, dangerous reagents are not used,reaction steps are shortened, and reaction efficiency is improved.

A synthesis method of a phenyl(quinolin-8-yl)-one derivative comprises the following steps: by taking 8-methylquinoline or substituted 8-methylquinoline and aryl iodide as raw materials, Ag2CO3 as an additive, KOAc as alkali and Pd(OAc)2 as a catalyst, reacting the raw materials in a solution formed by mixing hexafluoroisopropanol and glacial acetic acid according to a volume ratio of 3: 7, sealing a tube at 130 DEG C, and reacting for 24 hours to generate the target product. The synthesis process route is simple, and the highest yield reaches 87%.

The invention discloses 3,4-methylenedioxy methcathinone detection methods. One method in the invention performs organic solvent extraction on Methylone in a suspected drug sample, performs qualitative analysis by using gas chromatography-mass spectrography (GC-MS), and performs quantitative analysis on Methylone by using a gas chromatography-flame ionization detector (GC-FID). The other method inthe method performs organic solvent extraction on Methylone in the suspected drug sample, performs qualitative analysis in a multi-reaction monitoring (MRM) mode by using a liquid chromatography-tandem mass spectrometry (LC-MS/MS), and performs quantitative analysis on Methylone by using a liquid chromatography-diode array or ultraviolet detector (LC-DVD) or LC-UV).

The present invention relates to a method for the treatment of an inflammatory bowel disease by the administration of the compound [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, which may be represented as Formula I:

or a corresponding N-oxide, prodrug, pharmaceutically acceptable salt or solvate thereof.